Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 18 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-3.31 Insider Own26.13% Shs Outstand61.42M Perf Week-15.11%
Market Cap469.25M Forward P/E- EPS next Y-2.88 Insider Trans-0.71% Shs Float45.36M Perf Month18.63%
Income-215.79M PEG- EPS next Q-0.86 Inst Own91.35% Short Float20.75% Perf Quarter-7.51%
Sales0.00M P/S- EPS this Y0.78% Inst Trans-0.78% Short Ratio8.85 Perf Half Y-5.21%
Book/sh6.10 P/B1.25 EPS next Y10.51% ROA-38.05% Short Interest9.41M Perf Year-67.97%
Cash/sh6.85 P/C1.12 EPS next 5Y- ROE-46.42% 52W Range4.92 - 24.28 Perf YTD-9.37%
Dividend Est.- P/FCF- EPS past 5Y-19.52% ROI-48.33% 52W High-68.53% Beta1.22
Dividend TTM- Quick Ratio10.72 Sales past 5Y0.00% Gross Margin- 52W Low55.28% ATR (14)0.77
Dividend Ex-Date- Current Ratio10.72 EPS Y/Y TTM-6.12% Oper. Margin0.00% RSI (14)54.63 Volatility10.60% 11.63%
Employees331 Debt/Eq0.20 Sales Y/Y TTM- Profit Margin- Recom1.10 Target Price14.10
Option/ShortYes / Yes LT Debt/Eq0.19 EPS Q/Q-3.22% Payout- Rel Volume1.33 Prev Close7.81
Sales Surprise- EPS Surprise-6.76% Sales Q/Q- EarningsMay 16 BMO Avg Volume1.06M Price7.64
SMA2015.39% SMA5014.15% SMA200-22.97% Trades Volume1,411,554 Change-2.18%
Date Action Analyst Rating Change Price Target Change
Apr-17-23Resumed Piper Sandler Overweight $44
Nov-19-21Initiated Piper Sandler Overweight $52
Oct-15-21Resumed BTIG Research Buy $60
Nov-17-20Initiated BTIG Research Buy $60
Nov-02-20Initiated Jefferies Buy $67
Oct-15-20Upgrade H.C. Wainwright Neutral → Buy $25 → $54
Jul-01-20Downgrade H.C. Wainwright Buy → Neutral $25
May-05-20Initiated Barclays Overweight $21
Sep-04-19Initiated ROTH Capital Buy $20
Jul-23-19Initiated Chardan Capital Markets Buy $28
Jun-13-24 08:30AM
Jun-07-24 09:03AM
Jun-06-24 12:16PM
08:00AM Loading…
Jun-03-24 08:00AM
May-23-24 05:00PM
May-16-24 01:53PM
Apr-07-24 05:00PM
Apr-04-24 08:00AM
Mar-26-24 07:30AM
Mar-11-24 09:55AM
Mar-08-24 12:00PM
Mar-06-24 08:00AM
08:00AM Loading…
Mar-05-24 08:00AM
Feb-27-24 03:30AM
Feb-23-24 09:55AM
Feb-08-24 08:42AM
Jan-22-24 10:54AM
Jan-16-24 03:59AM
Dec-28-23 08:00AM
Dec-05-23 07:32AM
Nov-13-23 09:55AM
Nov-08-23 09:10AM
Nov-07-23 08:00AM
Nov-03-23 07:30PM
03:00AM Loading…
Oct-17-23 03:00AM
Sep-19-23 04:01PM
Sep-14-23 01:23PM
Aug-03-23 08:00AM
Aug-01-23 08:00AM
Jul-31-23 04:01PM
Jul-28-23 03:57PM
Jul-20-23 08:00AM
Jun-06-23 10:00AM
Jun-05-23 08:00AM
Jun-03-23 02:15PM
Jun-01-23 04:01PM
May-25-23 05:00PM
May-18-23 08:00AM
May-17-23 10:02AM
May-09-23 08:00AM
Mar-31-23 09:35AM
Mar-08-23 08:00AM
Feb-24-23 09:35AM
Feb-09-23 08:50AM
Feb-07-23 08:00AM
Jan-06-23 09:55AM
Jan-05-23 05:44AM
Jan-04-23 08:05AM
Jan-03-23 08:00AM
Dec-14-22 10:46AM
Dec-12-22 02:36PM
Dec-08-22 09:04PM
Dec-07-22 04:04PM
Nov-23-22 08:00AM
Nov-22-22 08:00AM
Nov-03-22 08:00AM
Nov-02-22 04:01PM
Oct-14-22 01:52PM
Oct-07-22 08:00AM
Aug-24-22 07:58AM
Aug-06-22 09:36AM
Aug-04-22 08:00AM
Aug-01-22 04:01PM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
May-30-22 06:42AM
May-26-22 05:15PM
May-19-22 08:00AM
May-03-22 08:55AM
Apr-14-22 01:35PM
Mar-30-22 07:00AM
Mar-21-22 08:00AM
Feb-11-22 08:00AM
Feb-03-22 08:00AM
Jan-31-22 04:01PM
Jan-10-22 07:00AM
Jan-04-22 08:00AM
Dec-17-21 09:35AM
Dec-08-21 07:38PM
Dec-02-21 08:00AM
Nov-12-21 07:00AM
Nov-04-21 08:00AM
Nov-01-21 08:00AM
Oct-01-21 08:01AM
Aug-09-21 09:52AM
Aug-06-21 08:00AM
Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Xynos KonstantinosChief Medical OfficerJun 07 '24Sale7.5015,881119,108117,131Jun 10 08:30 PM
Astley-Sparke PhilipExecutive ChairmanMay 16 '24Sale6.4737,928245,3941,487,350May 20 08:04 PM
Patel SushilChief Executive OfficerMay 16 '24Sale6.4720,194130,655212,014May 20 08:01 PM
Love ColinChief Operating OfficerMay 16 '24Sale6.4717,615113,969777,345May 20 08:05 PM
Coffin RobertDirectorMay 16 '24Sale6.4711,46474,1721,821,872May 20 08:02 PM
Xynos KonstantinosChief Medical OfficerMay 16 '24Sale6.476,36741,194133,012May 20 08:00 PM
Schwendenman AndrewChief Accounting OfficerMay 16 '24Sale6.472,29814,86838,238May 20 08:06 PM
Sarchi ChristopherChief Commercial OfficerMay 16 '24Sale6.472,21814,35092,252May 20 08:06 PM
Xynos KonstantinosChief Medical OfficerNov 16 '23Sale10.927,31379,858112,714Nov 17 08:01 PM
Sarchi ChristopherChief Commercial OfficerNov 16 '23Sale10.925,25557,38572,245Nov 17 08:00 PM
Esposito PamelaChief Business OfficerSep 12 '23Option Exercise3.30300990263,736Sep 13 09:02 PM
Esposito PamelaChief Business OfficerSep 12 '23Sale20.003006,000263,436Sep 13 09:02 PM
Esposito PamelaChief Business OfficerSep 11 '23Option Exercise3.305,35817,681268,794Sep 13 09:02 PM
Esposito PamelaChief Business OfficerSep 11 '23Sale20.015,358107,214263,436Sep 13 09:02 PM
Esposito PamelaChief Business OfficerAug 22 '23Option Exercise6.5818,600122,380282,036Aug 24 08:30 PM
Esposito PamelaChief Business OfficerAug 22 '23Sale20.0118,600372,186263,436Aug 24 08:30 PM
Esposito PamelaChief Business OfficerAug 11 '23Option Exercise3.301,4004,620264,836Aug 15 08:30 PM
Esposito PamelaChief Business OfficerAug 11 '23Sale20.001,40028,000263,436Aug 15 08:30 PM
Esposito PamelaChief Business OfficerJul 10 '23Option Exercise6.3520,000127,000283,436Jul 11 09:00 PM
Esposito PamelaChief Business OfficerJul 10 '23Sale21.5820,000431,541263,436Jul 11 09:00 PM